What Is the Beat AML Master Trial?

Ashley Yocum, PhD, Executive Research Strategy Lead at the Leukemia & Lymphoma Society, speaks about the Beat Acute Myeloid Leukemia (AML) study.

Beat AML is a precision medicine master study that assigns newly diagnosed or relapsed or refractory patients with AML to a biomarker-specific treatment within seven days based on targeted genomic sequencing in cytogenetics, Dr. Yocum said.

One of the findings from the trial was that patients had favorable outcomes if they received intensive chemotherapy over the other two treatment options in the study, she reported.

“For patients, it is very important for them to be able to have discussions with their oncologist to ensure that they have all of their genetic and cytogenetic information, as well as any of their other baseline characteristics that will help them make the best treatment decision,” Dr. Yocum said.